MADRIGAL PHARMACEUTICALS, INC. — Director's Dealing 2018

Nov 20, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: MADRIGAL PHARMACEUTICALS, INC. (MDGL)
CIK: 0001157601
Period of Report: 2018-11-19

Reporting Person: CRAVES FRED B (Director, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-11-19	Common Stock	P	100	$123.17	Acquired	296167	Direct
2018-11-19	Common Stock	P	1000	$124.57	Acquired	297167	Direct
2018-11-19	Common Stock	P	900	$125	Acquired	298067	Direct

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $124.00 to $124.82, inclusive. Thereporting person undertakes to provide to Madrigal Pharmaceuticals, Inc., any security holder of Madrigal Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.